tolterodine / Generic mfg. - LARVOL DELTA

Tamsulosin versus tamsulosin plus tolterodine for the treatment of distal ureteral stones. (PubMed, World J Urol) - "The combination of tamsulosin and tolterodine demonstrated superior efficacy in terms of stone expulsion rate and reduced expulsion time for distal ureteral stones compared to tamsulosin monotherapy. This combination therapy may offer a more effective medical expulsive therapy option for patients with distal ureteral calculi."

Clinical • Journal • Pain • Renal Calculi • Urology • Xerostomia

ADEER: Effect of Antimuscarinic Treatment on Premature Ejaculation Severity in Men With Overactive Bladder: a Prospective Comparison With Mirabegron (clinicaltrials.gov) - P=N/A | N=40 | Completed | Sponsor: Ba?ak?ehir am & Sakura City Hospital | N=60 ➔ 40

Enrollment change • Overactive Bladder • Sexual Disorders

ADEER: Effects of Antimuscarinic Drugs on Ejaculation Duration and Refractory Period in Men With Overactive Bladder (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Ba?ak?ehir am & Sakura City Hospital

New trial • Overactive Bladder • Sexual Disorders

Second- and third-line treatment options for refractory monosymptomatic enuresis in children: a scoping review. (PubMed, Eur J Pediatr) - "The results showed that, following first-line treatment, a combination of biofeedback, electrical nerve stimulations, anticholinergics (e.g. oxybutynin, tolterodine, solifenacin), β3-adrenoceptor agonists (e.g. vibegron), tricyclic antidepressants (e.g. imipramine) and selective serotonin reuptake inhibitor (e.g. fluoxetine) improved both partial response (PR) and complete response (CR) at varying rates across highly heterogeneous interventions and study populations...Furthermore, reports on electro-acupuncture, furosemide, onabotulinumtoxin A injections or the herbal medicine 'shokenchuto' were considered unreliable for pure refractory MNE, despite improvements in PR and CR occurring at different rates...Some second- and third-line treatment options may improve PR and CR rates, despite the limited available evidence to support a treatment algorithm. However, further research is needed to confirm these benefits."

Clinical • Journal • Review • Pediatrics • Urinary Incontinence

Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis. (PubMed, Eur J Obstet Gynecol Reprod Biol) - "Vibegron appears to rank more favourably for improvement in episodes of UU, UUI and maximum voided volume per void, when compared to mirabegron and tolterodine. Mirabegron ranks more favourably for improvement in episodes of urinary frequency over 24 h. Mirabegron is least likely to be associated with hypertension, although reporting of adverse events is non-standardised and therefore may not be comparable. This network meta-analysis does not account for other factors which may influence drug therapy choice i.e. contraindications, difficulties with swallowing and available treatment options."

Journal • Retrospective data • Review • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Hypertension • Infectious Disease • Nephrology • Overactive Bladder • Xerostomia

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease. (PubMed, Basic Clin Pharmacol Toxicol) - "Proton pump inhibitors (PPIs), opioids and non-benzodiazepine hypnotics (Z-drugs) were identified as common PIMs, whereas bladder antimuscarinics (tolterodine and solifenacin), sedating antihistamines (clemastine and promethazine) and antipsychotics with anticholinergic properties (quetiapine) were the most frequently used medications with strong anticholinergic properties. In conclusion, medication burden in patients with CKD is high, and incorporating PIMs and ACB scores may identify prescribing risks not captured by medication counts alone."

Journal • Retrospective data • Chronic Kidney Disease • CNS Disorders • Nephrology • Renal Disease

Analysis of the Effect of Stepwise Refined Nursing on the Severity of Ureteral Stent-Related Symptom Clusters After Flexible Ureteroscopic Lithotripsy. (PubMed, Arch Esp Urol) - "For patients undergoing FURL with indwelling ureteral stents, the application of stepwise refined nursing can effectively reduce the occurrence of postoperative complications, alleviate OAB symptoms and mitigate ureteral stent-related symptoms."

Journal • Overactive Bladder • Pain • Urinary Incontinence • Urology

A Prospective, Randomized Study Comparing Intravesical Micro-Radiofrequency Therapy to Oral Tolterodine in Patients with Newly Diagnosed Moderate-to-Severe Overactive Bladder (AUA 2026) - "Intravesical micro-RF therapy is an effective and safe minimally invasive treatment for moderate-to-severe OAB. It yields superior symptom improvement and a more favourable safety profile compared to oral tolterodine. These findings position micro-RF as a potential first-line therapeutic option for managing OAB."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Nephrology • Overactive Bladder • Xerostomia

Analysis of Temporal Trends in Anticholinergic and ß3 Agonist Prescription Patterns in the United States Pediatric Population (AUA 2026) - "Annual rates and cost of anticholinergic (darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium) and β3 agonist (mirabegron, vibegron) prescriptions were determined by drug type and insurance. Anticholinergic prescription rates in children decreased, with rates in the Medicaid and commercially insured populations converging. β3 agonist prescription rates were low but increased substantially and were higher among commercially insured patients. Anticholinergic costs were similar between groups, while β3 agonist prescriptions cost nearly twice as much for commercially insured patients."

Clinical • Alzheimer's Disease • CNS Disorders • Dementia • Overactive Bladder • Pediatrics

MULTI-TARGET THERAPEUTIC EFFECTS OF LEONURUS JAPONICUS IN DETRUSOR UNDERACTIVITY: RESTORATION OF BLADDER CONTRACTILITY THROUGH HYPOXIA ADAPTATION AND ANTI-APOPTOTIC MECHANISMS (AUA 2026) - "Leonurus japonicus demonstrates disease-modifying effects in DU through multi-target mechanisms including enhanced hypoxic adaptation, reduced apoptosis, and suppressed inflammation. Remarkably, LJE monotherapy outperformed combination with tolterodine in restoring bladder contractility, suggesting a novel ischemia-targeted therapeutic approach distinct from traditional antimuscarinic therapy. These findings warrant clinical investigation of intravesical LJE as a potential treatment for detrusor underactivity."

IO biomarker • Cardiovascular • Fibrosis • Immunology • Inflammation • Myocardial Ischemia • Reperfusion Injury • Urology • BCL2 • CASP3 • HIF1A • NFKB1 • TGFB1 • TNFA

Selective one-pot fluorescent probing technique for determination of tolterodine in dosage forms, content uniformity, and human plasma via coumarin synthesis. (PubMed, Talanta) - "This technique was successfully used for measuring TTD in its pure form, in the presence of co-formulated drug Tamsulosin Hydrochloride (TAM), and to assess pharmaceutical tablets for content uniformity. Additionally, environmental assessments using eco-scale, AGREE, and GAPI tools confirmed the method's eco-friendliness. This validated technique offers an efficient alternative for TTD analysis in pharmaceutical and biological matrices."

Journal • Overactive Bladder

Analysis of Major Impurities in Tolterodine Tartrate Tablets by 2D-UPLC-Q-TOF/MS. (PubMed, Rapid Commun Mass Spectrom) - "The established 2D-LC/MS method is effective for the structural elucidation and source tracking of impurities in tolterodine tartrate tablets. The identification of a process-related degradation product provides direct insights for enhancing formulation strategies and implementing targeted quality control measures."

Journal

Associations between Anticholinergic Use and Dementia Risk in a Prevalent-User Cohort: Analysis of Japanese Medication Histories as Real-World Data. (PubMed, Biol Pharm Bull) - "Among individual OAB anticholinergics, the ORs for oxybutynin (4.53; 95% CI: 2.18-9.42, p < 0.0001) and tolterodine (5.64; 95% CI: 2.42-13.17, p < 0.0001) were significant, whereas ORs for other OAB anticholinergics were not...In conclusion, analysis in this prevalent-user cohort study using medication history data showed a significant association between OAB anticholinergic use and increased dementia risk, with variation by drug. These results support the feasibility of utilizing medication history as real-world data for pharmacovigilance."

Journal • Real-world evidence • Retrospective data • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders • Overactive Bladder

Side effects of medical therapy for non-neurogenic lower urinary tract symptoms in children: a UK-based single centre retrospective case-note review. (PubMed, BMJ Paediatr Open) - "This study shows that oxybutynin and tolterodine were frequently discontinued due to SE, many of which are classified as 'psychiatric' or 'nervous system' disorders. Solifenacin and mirabegron were better tolerated: future research should investigate optimal medical therapy for LUTS in children."

Adverse events • Journal • Retrospective data • Overactive Bladder • Psychiatry • Urinary Incontinence • Urology

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain (clinicaltrials.gov) - P3 | N=26 | Terminated | Sponsor: Jocelyn Fitzgerald | Active, not recruiting ➔ Terminated; unable to reach the recruitment numbers required to power our primary outcome

Trial termination • Gynecology • Interstitial Cystitis • Musculoskeletal Pain • Pain

Efficacy and safety of first-line therapies and first-line-based combination therapies for monosymptomatic nocturnal enuresis in children: a network meta-analysis. (PubMed, Pediatr Nephrol) - "Desmopressin combined with anticholinergic agents significantly improved CR versus desmopressin monotherapy and demonstrated partial significant superiority over alarm therapy alone. Among these, desmopressin plus oxybutynin demonstrated the best overall efficacy. Alarm therapy and desmopressin alone showed similar therapeutic effectiveness. Desmopressin monotherapy was associated with a higher relapse rate. Importantly, combination therapy did not significantly increase the risk of AEs compared to monotherapies. According to the CINeMA framework, the certainty of evidence was mostly low to moderate, highlighting the need for cautious interpretation and further high-quality trials."

Journal • Retrospective data • Review • Urinary Incontinence

Clinical outcomes and safety of duloxetine and tolterodine combination in the treatment of mixed-type urinary incontinence: A single-arm retrospective study. (PubMed, J Int Med Res) - "Treatment-related adverse events were observed in 12.1% of patients.ConclusionThe combination therapy of duloxetine and tolterodine appears to be safe and potentially beneficial, reducing symptom scores and incontinence episodes. However, these findings need to be supported by controlled studies."

Clinical data • Journal • Retrospective data • Overactive Bladder • Urinary Incontinence • Urology

The effect of anticholinergics and β-3 agonists on erectile function: a narrative review. (PubMed, Sex Med Rev) - "OAB pharmacotherapy may influence male sexual health; however, evidence remains mixed. Further high-quality research is needed to elucidate these relationships and guide individualized treatment strategies that address both urinary and sexual function in men."

Journal • Overactive Bladder

Development of the synthetic route to 5-hydroxymethyl tolterodine, a key synthetic intermediate of Toviaz, via an organic solvent-free Rh-catalyzed asymmetric 1,4-addition. (PubMed, Org Biomol Chem) - "A synthetic route to Toviaz (fesoterodine fumarate) and its key intermediate 5-hydroxymethyl tolterodine (5-HMT) was markedly improved by employing an organic solvent-free rhodium-catalyzed asymmetric 1,4-addition. Under these conditions, the reactivity depended strongly on the substrates' melting points, even though the reaction temperature was more than 20 °C below them."

Journal

TRIUMPH: TReating Incontinence for Underlying Mental and Physical Health (clinicaltrials.gov) - P4 | N=270 | Recruiting | Sponsor: University of California, San Francisco | Trial completion date: Jan 2027 ➔ Aug 2027 | Trial primary completion date: Nov 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Overactive Bladder • Urinary Incontinence • Urology

GLANCE-aided snapshotting for sustainable integration of synchronous spectrofluorimetry and micellar boosting for nanoscale assay of tolterodine binary mixtures in crucial matrices. (PubMed, Sci Rep) - "Tolterodine tartrate (TLD) has recently demonstrated remarkable synergism when combined with either of two α1-adrenergic antagonists, doxazosin mesilate (DXZ) or terazosin hydrochloride dihydrate (TRZ), for treating urinary tract issues. The outcomes demonstrated the excellence of the designed methodology over reported approaches, offering proficient sensitivity, sustainability, facility, and practicability across diverse crucial matrices. These findings provide compelling evidence that the proposed work serves as an efficient, eco-friendly quantification tool for use in quality control, biological, and environmental sectors, fostering a more eco-conscious and sustainable scientific community."

Journal

Enantiodivergent Rh-Catalyzed Reductive Hydroformylation of Alkenyl Boronic Esters. (PubMed, Angew Chem Int Ed Engl) - "The chiral γ-boryl alcohol or diol products are versatile building blocks applicable to the synthesis of a series of APIs including (S)-tolterodine, (S)-dapoxetine, and (R)-atomaxetine. DFT calculation has revealed the origin of enantiodivergence of Rh-catalyzed reductive AHF of alkenyl boronic esters with Ph-BPE as the chiral ligand. The transformation is promised to provide great synthetic potential in both academia and industry."

Journal

Response to anticholinergic therapy and its predictors in pediatric overactive bladder. (PubMed, Eur J Pediatr) - P | "Anticholinergics show similar efficacy in treating OAB, though oxybutynin is associated with more side effects. Tolterodine reduced the odds of non-complete response, while a higher daily voids increased it."

Journal • Retrospective data • Overactive Bladder • Pediatrics

A randomized controlled study on the treatment for children with spleen-kidney qi deficiency type neurogenic urination (ChiCTR) - P=N/A | N=102 | Not yet recruiting | Sponsor: Beijing Children’s Hospital, Capital Medical University; Beijing Children’s Hospital, Capital Medical University

New trial

Evaluation of the Potential Inhibitory Effects of Medications for Detrusor Overactivity on Platelet-Activating Factor (PAF)-Induced Mechanical Activity in Guinea Pig Bladder Smooth Muscle. (PubMed, Biol Pharm Bull) - "Ten clinically used DO drugs-oxybutynin, tolterodine, fesoterodine, propiverine, propantheline, solifenacin, imidafenacin, flavoxate, urapidil, and clenbuterol-were tested at a concentration of 10 μM, exceeding typical therapeutic plasma levels. Furthermore, oxybutynin (10 μM) also decreased 60 mM KCl-induced contractions by a similar extent and nearly abolished acetylcholine (ACh, 10 μM)-induced contractions. These findings suggest that oxybutynin suppresses PAF-induced UBSM hyperactivity through a mechanism distinct from its anticholinergic effect, likely mediated by blockade of voltage-dependent Ca2+ channels (VDCCs)."

Journal • Overactive Bladder